title: Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes.
abstract: The activity of fenticonazole was studied against 260 West and Southeast European vulvovaginal candidiasis isolates, and low MICs were displayed. Fenticonazole was assessed by European Committee on Antimicrobial Susceptibility Testing and CLSI microdilution methods for the first time, and the results showed excellent agreement (97%) and significant interclass correlation coefficient (P < 0.0001). Also, the levels of agreement for the results for itraconazole, fluconazole, and ketoconazole were 84%, 90%, and 98% (P < 0.0001), respectively. Multilocus typing by PCR fingerprinting and subsequent cluster analysis delineated geographically associated alignments for Candida albicans and fluconazole resistance-related clusters for Candida glabrata.
authors.affiliation: Department of Bacteriology and Biochemistry, University of Athens, Aretaieion Hospital Athens, Athens, Greece.
authors.forename: Stavroula
authors.initials: S
authors.lastname: Antonopoulou
authors.forename: Michel
authors.initials: M
authors.lastname: Aoun
authors.forename: Evangelos C
authors.initials: EC
authors.lastname: Alexopoulos
authors.forename: Stavroula
authors.initials: S
authors.lastname: Baka
authors.forename: Emanuel
authors.initials: E
authors.lastname: Logothetis
authors.forename: Theodoros
authors.initials: T
authors.lastname: Kalambokas
authors.forename: Andreas
authors.initials: A
authors.lastname: Zannos
authors.forename: Konstantine
authors.initials: K
authors.lastname: Papadias
authors.forename: Odysseas
authors.initials: O
authors.lastname: Grigoriou
authors.forename: Evangelia
authors.initials: E
authors.lastname: Kouskouni
authors.forename: Aristea
authors.initials: A
authors.lastname: Velegraki
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology*; D002176:Candida albicans / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D041221:Candida glabrata / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D002181:Candidiasis, Vulvovaginal / Q000453:epidemiology* / Q000382:microbiology*; D016000:Cluster Analysis; D016172:DNA Fingerprinting / Q000379:methods; D025141:Drug Resistance, Fungal; D005060:Europe / Q000453:epidemiology; D005260:Female; D015725:Fluconazole / Q000494:pharmacology; D005838:Genotype; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D017964:Itraconazole / Q000494:pharmacology; D007654:Ketoconazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000592:standards; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology / Q000382:microbiology; D015995:Prevalence
chemical_list: D000935:Antifungal Agents; D007093:Imidazoles; D017964:Itraconazole; D015725:Fluconazole; C033486:fenticonazole; D007654:Ketoconazole